Fc Engineered Anti-Human IL-23 p19 Antibody, CDC-Enhanced (Biobet-C052ZP) (CAT#: Biobet-C052ZP) Datasheet

IL-23 p19

Whole Humanized Antibody

CDC-Enhanced Tildrakizumab is a Fc-modified anti-IL-23 p19 therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Tildrakizumab, Tildrakizumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.

Plaque psoriasis

Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.